Top Markets
#1 0G 0G +29.20%
#2 SAFEcoin SAFEcoin +21.02%
#3 Cysic Cysic +20.97%
#4 Zora Zora +19.25%
#5 Full Moon Full Moon +18.99%
#6 Axelar Axelar +18.01%
#7 Merlin's Seal BTC Merlin's Seal BTC +16.73%
#8 StonkBroker StonkBroker +16.18%
#9 VVS Finance VVS Finance +15.88%
#10 AI XOVIA AI XOVIA +15.87%
Coin of the day
0G 0G
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Silverback Therapeutics, Inc. Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc.

SBTX
Rangering i aksjer #12783
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to... Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.
Aksjekurs
$5.87
Sist synkronisert: 2022-11-08
Markedsverdi
$550.43M
Endring (1 dag)
1.03%
Endring (1 år)
0.00%
Land
US
Handel Silverback Therapeutics, Inc. (SBTX)

Kategori

Healthcare
Inntekter for Silverback Therapeutics, Inc. (SBTX)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Silverback Therapeutics, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Silverback Therapeutics, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH